Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > pre-BTD and BTD

<< Previous

Bullboard Posts

Next >>

Comment by DJDawgon Nov 07, 2023 8:30am

213 Views

Post# 35720996

RE:RE:RE:RE:RE:pre-BTD and BTD

I think that if the amended protocol just leads to some patients getting treatments at 0,3,6 m vs now 0 and 6m, they will still look really good if that CR holds from 12 m after the last treatment.

If a few get a 2nd treatment at 9 or 12 m then those won't be interpreted quite the same way. I believe that the modification is partly about getting patient's to stay in the trial for the full 6 m rather than opting out at 3m when they get an NR results.

So overall, if you are CR from 6 to 18 months, that would still look good for AA, IMO.

<< Previous

Bullboard Posts

Next >>

First Nations contributions attract investor interest